Cash and Cash Equivalents: As of March 31, 2025, the company had cash and cash equivalents of $13.9 million, compared to $23.3 million as of December 31, 2024. The company believes its cash balance as ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Monopar Therapeutics Inc.’s MNPR share price has dipped by 5.26%, which has investors questioning if this is right time to buy.